Serum inflammatory factors are positively correlated with the production of specific antibodies in coronavirus disease 2019 patients.
作者信息
Zheng Meijuan, Gao Yong, Liu Siyu, Sun Dandan, Yang Fan, Zong Lu, Zhang Min, Tian Zhigang, Xu Yuanhong, Sun Haoyu
机构信息
Department of Clinical Laboratory, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Department of Clinical Laboratory, Fuyang Second People's Hospital, Fuyang, Anhui, China.
出版信息
Cell Mol Immunol. 2020 Nov;17(11):1180-1182. doi: 10.1038/s41423-020-00551-1. Epub 2020 Sep 22.
Abstract
摘要
相似文献
1
Serum inflammatory factors are positively correlated with the production of specific antibodies in coronavirus disease 2019 patients.
Cell Mol Immunol. 2020 Nov;17(11):1180-1182. doi: 10.1038/s41423-020-00551-1. Epub 2020 Sep 22.
2
Protective humoral immunity in SARS-CoV-2 infected pediatric patients.
Cell Mol Immunol. 2020 Jul;17(7):768-770. doi: 10.1038/s41423-020-0438-3. Epub 2020 May 7.
3
Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients.
Sci Immunol. 2020 Oct 8;5(52). doi: 10.1126/sciimmunol.abe5511.
4
Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19.
Nat Med. 2020 Apr;26(4):453-455. doi: 10.1038/s41591-020-0819-2.
5
Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection.
J Microbiol Immunol Infect. 2020 Oct;53(5):821-822. doi: 10.1016/j.jmii.2020.03.015. Epub 2020 Mar 25.
6
Double-Edged Spike-Are SARS-CoV-2 Serologic Tests Safe Right Now?
Lab Med. 2020 May 6;51(3):236-238. doi: 10.1093/labmed/lmaa025.
7
Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.
Immunity. 2020 Jun 16;52(6):971-977.e3. doi: 10.1016/j.immuni.2020.04.023. Epub 2020 May 3.
8
Serum IgA, IgM, and IgG responses in COVID-19.
Cell Mol Immunol. 2020 Jul;17(7):773-775. doi: 10.1038/s41423-020-0474-z. Epub 2020 May 28.
9
Distinct Early Serological Signatures Track with SARS-CoV-2 Survival.
Immunity. 2020 Sep 15;53(3):524-532.e4. doi: 10.1016/j.immuni.2020.07.020. Epub 2020 Jul 30.
10
Recovered COVID-19 patients with recurrent viral RNA exhibit lower levels of anti-RBD antibodies.
Cell Mol Immunol. 2020 Oct;17(10):1098-1100. doi: 10.1038/s41423-020-00528-0. Epub 2020 Sep 16.
引用本文的文献
1
Innate immune imprints in SARS-CoV-2 Omicron variant infection convalescents.
Signal Transduct Target Ther. 2022 Nov 16;7(1):377. doi: 10.1038/s41392-022-01237-y.
2
Plasticity of natural killer cells in pregnant patients infected with SARS-CoV-2 and their neonates during childbirth.
Front Immunol. 2022 Jul 15;13:893450. doi: 10.3389/fimmu.2022.893450. eCollection 2022.
3
Considerations for Novel COVID-19 Mucosal Vaccine Development.
Vaccines (Basel). 2022 Jul 23;10(8):1173. doi: 10.3390/vaccines10081173.
4
Landscape of Peripheral Blood Mononuclear Cells and Soluble Factors in Severe COVID-19 Patients With Pulmonary Fibrosis Development.
Front Immunol. 2022 Apr 26;13:831194. doi: 10.3389/fimmu.2022.831194. eCollection 2022.
5
Asymptomatic SARS-CoV-2 infection in an unvaccinated 97-year-old woman: A case report.
Biomed Rep. 2021 Dec;15(6):107. doi: 10.3892/br.2021.1483. Epub 2021 Oct 28.
6
Modulation of Host Immune Response Is an Alternative Strategy to Combat SARS-CoV-2 Pathogenesis.
Front Immunol. 2021 Jul 8;12:660632. doi: 10.3389/fimmu.2021.660632. eCollection 2021.
7
SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation.
Clin Transl Immunology. 2021 Jul 5;10(7):e1306. doi: 10.1002/cti2.1306. eCollection 2021.
8
Enzyme kinetic and binding studies identify determinants of specificity for the immunomodulatory enzyme ScpA, a C5a inactivating bacterial protease.
Comput Struct Biotechnol J. 2021;19:2356-2365. doi: 10.1016/j.csbj.2021.04.024. Epub 2021 Apr 17.
9
Road Map to Understanding SARS-CoV-2 Clinico-Immunopathology and COVID-19 Disease Severity.
Pathogens. 2020 Dec 23;10(1):5. doi: 10.3390/pathogens10010005.
本文引用的文献
1
Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients.
Natl Sci Rev. 2020 Jun;7(6):998-1002. doi: 10.1093/nsr/nwaa041. Epub 2020 Mar 13.
2
A dynamic COVID-19 immune signature includes associations with poor prognosis.
Nat Med. 2020 Oct;26(10):1623-1635. doi: 10.1038/s41591-020-1038-6. Epub 2020 Aug 17.
3
Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis.
Nature. 2020 Dec;588(7836):146-150. doi: 10.1038/s41586-020-2600-6. Epub 2020 Jul 29.
4
Immunology of COVID-19: Current State of the Science.
Immunity. 2020 Jun 16;52(6):910-941. doi: 10.1016/j.immuni.2020.05.002. Epub 2020 May 6.
5
Human neutralizing antibodies elicited by SARS-CoV-2 infection.
Nature. 2020 Aug;584(7819):115-119. doi: 10.1038/s41586-020-2380-z. Epub 2020 May 26.
6
Antibody responses to SARS-CoV-2 in patients with COVID-19.
Nat Med. 2020 Jun;26(6):845-848. doi: 10.1038/s41591-020-0897-1. Epub 2020 Apr 29.
7
The trinity of COVID-19: immunity, inflammation and intervention.
Nat Rev Immunol. 2020 Jun;20(6):363-374. doi: 10.1038/s41577-020-0311-8. Epub 2020 Apr 28.
8
Translating IL-6 biology into effective treatments.
Nat Rev Rheumatol. 2020 Jun;16(6):335-345. doi: 10.1038/s41584-020-0419-z. Epub 2020 Apr 23.
9
Deployment of convalescent plasma for the prevention and treatment of COVID-19.
J Clin Invest. 2020 Jun 1;130(6):2757-2765. doi: 10.1172/JCI138745.
10
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.
Trends Immunol. 2020 May;41(5):355-359. doi: 10.1016/j.it.2020.03.007. Epub 2020 Apr 2.
Zotero 插件